ROS overproduction has been observed in melanoma, glioma, nasopharyngeal carcinoma, cholangiocarcinoma, colon cancer, and primary effusion lymphoma cells after SHK treatment (42–44; 45; 46). This evidence concerns the gene SHPK and glioma.